Authors
Ludvig M Sollid
Published in
Proceedings of the National Academy of Sciences of the United States of America. Volume 123. Issue 37. Pages e2600933123. Sep 15, 2026. Epub Sep 04, 2026.
Abstract
Celiac disease (CeD) and rheumatoid arthritis (RA) share several key features. In both diseases HLA class II allotypes are the major genetic determinants, in both diseases there are antibodies to posttranslationally modified peptides (i.e., deamidated peptides in CeD and citrullinated peptides in RA) and in both diseases there are autoantibodies to enzymes that mediate these peptide modifications (i.e., transglutaminase 2 for CeD and peptidyl arginine deiminase 2 and 4 for RA). In CeD, recent insights obtained from studies of antigen-specific immune cells have established a mechanistic model that integrates these key features by a pivotal involvement of enzyme-substrate complexes. Conceivably, the pathomechanism of RA parallels that of CeD in which autoreactive B cells by internalizing enzyme-substrate complexes present posttranslationally modified peptides to CD4+ T cells. This pathomechanism places enzyme-reactive B cells in the center of events. This notion resonates well with B cell depleting therapies being successfully explored for RA. A shared pathomechanism raises the possibility that RA, like exogenous cereal gluten proteins drive immunopathology in CeD, is driven by T cell reactions to foreign antigen.
PMID:
42696555
Bibliographic data and abstract were imported from PubMed on 05 Sep 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 5
- Comments 0